Analysts anticipate DR Horton will report fiscal second-quarter revenue of $7.66 billion and EPS of $2.15, with the stock currently trading at $149.81 relative to a $160.00 consensus price target.
Investors are primarily focused on net sales orders, which are projected to grow approximately 6.2% year-over-year to 23,826 homes.
While demand is supported by a significant lack of existing home inventory, persistent affordability constraints and elevated mortgage rates remain headwinds. To maintain closing volumes, the company has relied heavily on sales incentives and mortgage rate buy-downs, which are expected to compress home sales gross margins into the 19.0% to 19.5% range.